This work was supported by an educational grant from Amgen, Inc. The content and opinions expressed in this article are those of the authors alone. Background. The route of Epoetin alfa (EPO) administration has become a controversial issue in recent years. Despite the National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF-DOQI) guidelines recommending subcutaneous (SC) EPO for all dialysis patients, only 12 % of hemodialysis patients in the U.S. receive EPO by the SC route. Methods. A telephone survey was undertaken to gather opinions and clinical practice information regarding the choice of EPO route of administration. Sixteen people from several different vantage points within the dialysis community were interviewed about a variety of factors related to route of EPO therapy including clinical outcomes, financial aspects, impact on staff workload, and patient preferences. Six interviewees were specifically chosen to represent programs i
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.